GAO testifies on malpractice insurance
This article was originally published in The Gray Sheet
Losses on medical claims "appear to be the primary driver of [health insurance premium] rate increases," GAO Medicaid Director Kathryn Allen and Financial Markets Director Richard Hillman testify before the House Government Reform/Wellness & Human Rights Subcomittee Oct. 1. However, "in order for Congress to understand the market...better data need to be collected," GAO concludes. Manufacturers are mobilizing against increasing malpractice claims, purported to be deleterious to medical technology (1"The Gray Sheet" Aug. 18, 2003, p. 15)...
You may also be interested in...
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.